Phase 4 study of trastuzumab deruxtecan for HER2-positive solid tumors (DP-04)

Who Can Participate?

Age Range

18-110
Looking for Healthy Participants
No

What is Involved?

Locations

Duke University Hospital
Duke Raleigh Hospital

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

No

Study Details

Full Title

[D4327R00001] Effectiveness of T-DXd across HER2-positive solid tumors in patients who have received prior systemic treatment and have no satisfactory alternative treatment options: A hybrid observational study

Principal Investigator

Aman
Opneja

Protocol Number

PRO00118385

Phase

IV

Enrollment Status

Open to Enrollment